Selective cancer targeting via aberrant behavior of cancer cell-associated glucocorticoid receptor

Area of Science:

• Molecular Biology
• Cancer Research
• Gene Therapy

Background:

• Glucocorticoid receptors (GRs) are nuclear hormone receptors found in both cancer and normal cells.
• Selective manipulation of cancer cell-associated GR for gene delivery remains unexplored.
• Understanding GR's role in cancer cells is crucial for targeted therapies.

Purpose of the Study:

• To investigate the selective manipulation of cancer cell-associated GR for targeted gene delivery.
• To evaluate the potential of GR-targeted lipoplex in cancer treatment.
• To explore the role of Hsp90 in GR-targeted lipoplex uptake in cancer cells.

Main Methods:

• Development of a GR-targeted lipoplex using dexamethasone (Dex).
• Transfection experiments in various cancer and normal cell types.
• Assessment of GR downregulation effects on transfection efficiency.
• In vivo studies using mice to evaluate tumor growth retardation.
• Investigation of Hsp90's role in lipoplex uptake and GR activation.

Main Results:

• Targeted lipoplex demonstrated GR-specific transfection in all tested cancer cells.
• Transfection efficiency significantly decreased in cancer cells with downregulated GR.
• Specific nuclear translocation of lipoplex in cancer cells led to GRE-promoted gene upregulation.
• Targeted lipoplex significantly inhibited tumor growth in mice.
• Cell surface Hsp90 facilitated lipoplex uptake in cancer cells, while its inhibition in normal cells induced aberrant GR activation.

Conclusions:

• Cancer cell-associated GR can be selectively targeted for gene delivery using Dex-associated lipoplex.
• This GR-targeted approach shows therapeutic potential for cancer treatment by inhibiting tumor growth.
• Hsp90 plays a key role in the selective uptake of GR-targeted lipoplex by cancer cells.